Drug intelligence / Profile preview

Endocine

Development stage: Unknown
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intranasal

Overview

Endocine is a lipid-based mucosal adjuvant designed to enhance immune responses. It is administered intranasally and has been studied in conjunction with therapeutic HIV vaccines (Vacc-4x) and influenza antigens to induce both systemic and mucosal immunity. Its mechanism of action involves mediating RNA release, which subsequently activates dendritic cells, thereby improving vaccine efficacy, particularly in populations like the elderly.

Brand names: Endocine™

Beyond the preview

Go deeper on Endocine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endocine.

Explore the full profile